ArticleCureus2025
Successful Treatment of Acquired von Willebrand Syndrome in a Rare Case of Nodal Marginal Zone Lymphoma With Rituximab Therapy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nodal marginal zone lymphoma (NMZL) is an uncommon, mature B-cell lymphoma, rarely associated with acquired von Willebrand syndrome (AVWS), a bleeding disorder caused by von Willebrand factor (VWF) defects secondary to lymphoproliferative disorders (LPDs). We report a 68-year-old woman with longstanding Sjögren's syndrome, presenting with persistent oral bleeding, anemia, prolonged activated partial thromboplastin time (APTT, 50.5 seconds), and IgA-λ monoclonal gammopathy. Further investigation revealed severely decreased VWF ristocetin cofactor activity (VWF:RCo, 16%). Imaging revealed systemic lymphadenopathy, and a lymph node biopsy confirmed NMZL. The patient was treated with four weekly doses of rituximab, resulting in cessation of bleeding, improvement of coagulation parameters, resolution of anemia, and significant lymphadenopathy regression - consistent with complete response by computed tomography (CT) per Lugano 2014. This case highlights the diagnostic challenges of AVWS associated with NMZL and demonstrates rituximab's efficacy in treating both lymphoma and AVWS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.